ASX Announcement
27 May 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Completes Cloud-based Telepathology Software MVP

Optiscan has progressed its cloud-based telepathology streaming software project to Minimum Viable Product (MVP) stage, representing a major milestone in the Company's ability to offer real-time digital pathology solutions.

Highlights

- Optiscan has successfully completed the prototype of its cloud-based telepathology streaming software solution marking the project's completion of the MVP stage.
- The software enables remote access to high-resolution, real-time digital pathology imaging - all in one secure cloud platform.
- This software allows pathologists to review sessions, flag images, generate reports and collaborate with imaging clinicians via the cloud.
- The solution is designed as Software as a Medical Device (SaMD) which is compatible with Optiscan's growing suite of medical devices, namely InVue®, InForm™, and InVivage®.

Optiscan Imaging Limited (ASX:OIL) ('**Optiscan**' or the '**Company**') is pleased to announce the successful completion of the MVP phase for its cloud-based telepathology software solution, developed in collaboration with Canada-based software developer Prolucid Technologies.

This represents a key milestone in transforming digital pathology. Optiscan's telepathology software solution integrates its proprietary confocal imaging technology to allow clinicians and pathologists to collaborate in real-time, regardless of location. This advancement removes the traditional limitations of geography and infrastructure, empowering healthcare providers to make immediate, informed decisions at the point of care.

At its core, the platform enables secure live streaming of digitally native microscopic imaging sessions, allowing pathologists and other experts to remotely access and interpret high-resolution images generated by clinicians in real time. Additional features such as image annotation, session review, and report generation enhance the utility of the system and streamline post-session workflows.

The MVP prototype has been developed with upgraded device software and a robust cloud infrastructure, designed to support seamless, real-time collaboration between clinicians and pathologists. To ensure data security and privacy, the platform uses secure logins, encryption, and strict access controls. Personal details are hidden to protect patient identity, and no patient data is transferred through the system. All captured images are uploaded to the cloud for secure storage and can be accessed when needed without compromising confidentiality.

The Optiscan Telepathology solution has been designed with data privacy and security at its core. At the time of deployment, Optiscan devices are onboarded to the cloud platform using certificates to ensure only authenticated equipment are registered. Only registered devices are allowed to access the platform, and the platform authorises each session as another layer of protection. All communications are handled over secure channels.

Clinicians can schedule imaging sessions and can invite registered pathologists for synchronous consultations, while pathologists can access the system for asynchronous annotation and report generation if they wish. This distributed, synchronous, and near real-time remote access is facilitated through the cloud-based platform, which establishes peer-to-peer connections using the WebRTC protocol with typical end-to-end latency of less than 500 milliseconds (half a second) along with built in QoS (quality of service) ensuring all acquired images are available to the end user. External participants – such as consulting specialists – can be securely invited to join the streaming imaging sessions further enhancing second consultations and provision of opinion which is customary in pathology practice. All patient information is encrypted and is only stored locally on the device, and the platform generates anonymised reports by default, but supports patient-identified reporting if required. Real-time image flagging is designed to assist with future analysis and offline image annotation to support post-session review.

The next phase of the telepathology platform project will focus on validating the platform in real-world settings, incorporating user feedback, and preparing for broader clinical deployment.

Dr Camile Farah, CEO and Managing Director of Optiscan, said: "The collaboration with Prolucid has enabled our team to develop a seamless and secure workflow that bridges the gap between onsite real-time microscopic imaging and real-time remote pathology interpretation. This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural, and remote healthcare settings where access to pathology expertise is limited. By removing these barriers, we're bringing high-quality digital pathology to anyone, anywhere, anytime. Our telepathology solution essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology."

Darcy Bachert, CEO of Prolucid Technologies, commented: "The Optiscan telepathology platform will revolutionize patient care by bringing the pathology lab straight to the bedside, ensuring real-time diagnostics and swift, life-saving decisions. Developing this prototype with the Optiscan team demonstrates a major step forward in delivering a secure, scalable, and intuitive platform that brings real-time imaging and remote collaboration together. It's a powerful example of how technology can break down barriers in healthcare and enable smarter, faster decision-making at the point of care."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
T: +61 3 9538 3333
E: ceo@optiscan.com

Media & Investor Enquiries
The Capital Network
Julia Maguire
T: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn, X or Instagram.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.